The results of this study demonstrated that IL-16-targeted contrast imaging agents bound with their targets expressed by ovarian tumors at early and late stages in hens and enhanced the intensities of ultrasound imaging signals from these tumors. The gene discussed is IL16; the disease is ovarian neoplasm.